|
DBT Initiative To Assess Quality Of Medical
Devices
The Germany based Cinvention AG, a leading technology company
focusing on a nano-composite materials in biomedical applications is pitching on
drug eluting stents market globally.
The Department of Biotechnology (DBT) under the Science and
Technology Ministry is taking steps to assess the quality of existing medical
devices and implants in the country, besides analyzing the possible scope of the
market.
The DBT has already invited technical and financial bids from
the individuals and institutions of expertise to conduct the proposed study with
a futuristic outlook. The study, to completed in two months, will cover the
entire spectrum of medical devices, implants and bioinstrumentation, sources
said.
The survey will assess the imports and exports of the
devices, key industries using them and the development of market for the next
five years. It will also examine the hurdles in the sector for the future growth
and barriers to the technology transfer and investment from overseas.
Suddenly the medical devices market in the country is
witnessing a spur with the stakeholders joining together to expand the reach and
more international players coming to India.
The Government on the other hand is planning a legislation to
benchmark the devices which throw open huge export potentials.
(Ref : Chronicle Pharmabiz dated December 21, 2006)
Cinvention Sees Huge Potential For Drug
Eluting Stents Market
Cinvention has focused on the use of non-thrombogenic
materials that help in avoiding the potential complications that are identified
as major concerns with the drug eluting stents.
Relisys Medical Devices for manufacturing and global
marketing of a coronary stent with a bio-active nano-structured carbon-composite
coating with pro-healing properties. It has just finalised another deal with a
Japanese firm.
Dr Soheil Asgari, CEO and CTO of Cinvention told Pharmabiz
that the drug eluting stents market worldwide has been growing at a steady pace.
There were about 2.2 lakh implants in Germany alone, last year, while India
registered over 1 lakh implants.
The US accounts for about 50 per cent of the stents market,
while Europe occupies 25 per cent of the market. Japan through small in volume
is a high value market contributing for about 10 per cent of the market.
A stent which may cost $ 3000 in the US, and $ 1800 in
Europe, can cost about $5000 in Japan. Doctor per patient ratio is also high in
Japan, making it one of the most potential markets for stents, he added.
(Ref : Chronicle Pharmabiz dated December 21, 2006) |
